Monoclonal Anti-Claudin 1 Antibodies for the Inhibition of Hepatitis C Virus Infection
AssigneesGenovac, Universite De Strasbourg, Inserm (Institut National De La Sante Et De La Recherche Medicale)
InventorsThomas Baumert, Catherine Schuster, John Thompson, Fritz Grunert
Life of this patent
Estimating the term…
Abstract
The present invention provides monoclonal antibodies that specifically bind to the extracellular domain of human Claudin-1 on the cell surface, thereby inhibiting HCV entry into susceptible cells and preventing HCV infection of these cells; and hybridoma cell lines which produce such monoclonal antibodies. Also provided are reagents that comprise such antibodies, and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing HCV infection by administration of an inventive monoclonal antibody, or a pharmaceutical composition thereof are also described.
Claims24
1-24. (canceled)
A hybridoma cell line deposited at the DSMZ on Jul. 29, 2008 under an Accession Number selected from the group consisting of DSM ACC2931, DSM ACC2932, DSM ACC2933, DSM ACC2934, DSM ACC2935, DSM ACC2936, DSM ACC2937, and DSM ACC2938.
A monoclonal antibody secreted by a hybridoma cell line deposited at the DSMZ on Jul. 29, 2008 under an Accession Number selected from the group consisting of DSM ACC2931, DSM ACC2932, DSM ACC2933, DSM ACC2934, DSM ACC2935, DSM ACC2936, DSM ACC2937, and DSM ACC2938, or a biologically active fragment thereof that binds Claudin 1 extracellular domain.
A monoclonal antibody comprising the complementary determining regions (CDRs), or portions thereof, derived from a monoclonal antibody secreted by a hybridoma cell line deposited at the DSMZ on Jul. 29, 2008 under an Accession Number selected from the group consisting of DSM ACC2931, DSM ACC2932, DSM ACC2933, DSM ACC2934, DSM ACC2935, DSM ACC2936, DSM ACC2937, and DSM ACC2938, or a biologically active fragment thereof that binds Claudin 1 extracellular domain.
Dependencies are inferred from the claim text.